You
are here: Home: CCU 3 | 2003: Norman
Wolmark, MD: Select publications
Select publications
Publications discussed by Dr Wolmark
Benson AB et al. Bevacizumab (anti-VEGF) plus FOLFOX4
in previously treated advanced colorectal cancer (advCRC): An interim toxicity
analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc ASCO 2003;Abstract 975.
DeGramont A et al. Oxaliplatin/5-FU/LV in adjuvant colon
cancer: Results of the international randomized MOSAIC trial. Proc ASCO 2003;Abstract 1015.
Gamelin E et al. Prevention of oxaliplatin peripheral
sensory neuropathy by Ca+ gluconate/Mg+ chloride infusions: A retrospective
study. Proc ASCO 2002;Abstract
624.
Giantonio BJ et al. Bevacizumab (anti-VEGF) plus IFL
(irinotecan, fluorouracil, leucovorin) as frontline therapy for advanced
colorectal cancer (advCRC): Results from the Eastern Cooperative Oncology
Group (ECOG) Study E2200. Proc ASCO 2003;Abstract
1024.
Hurwitz H et al. Bevacizumab (a monoclonal antibody
to vascular endothelial growth factor) prolongs survival in first-line colorectal
cancer (CRC): Results of a Phase III trial of bevacizumab in combination
with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy
in subjects with metastatic CRC. Proc ASCO 2003:Abstract 3646.
Smith RE et al. UFT/leucovorin vs 5-FU/leucovorin in
colon cancer. Oncology
(Huntingt) 2000;14(10 Suppl 9):24-7. Abstract
|
